Retatrutide vs Tirzepatide vs Semaglutide: Full Research Comparison

The incretin system is the metabolic control loop that regulates insulin release, appetite and energy handling after meals. All three peptides are engineered once-weekly agonists built on that system, but they engage different combinations of receptors.

• Semaglutide (Novo Nordisk) activates only the glucagon-like peptide-1 (GLP-1) receptor. It is the reference single-agonist compound, best known from the STEP obesity program.
• Tirzepatide (Eli Lilly) is a dual agonist at the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, studied in the SURMOUNT obesity program and the SURPASS diabetes program.
• Retatrutide (Eli Lilly) is a first-in-class triple agonist targeting the GIP, GLP-1 and glucagon (GCG) receptors simultaneously.

The practical question is whether adding receptor targets produces a better research outcome or simply a more complicated one. The available data suggests it produces both: more efficacy at the top end, and more variables to control.

A clean way to compare the three compounds is to drop the marketing shorthand and look at what each receptor contributes to the pharmacology.

• GLP-1 receptor agonism drives satiety signaling in hypothalamic and hindbrain circuits, delays gastric emptying and improves glucose-dependent insulin secretion. Every compound in this comparison has it.
• GIP receptor agonism enhances insulinotropic signaling and appears to shape adipose tissue handling. Tirzepatide and retatrutide both carry it.
• Glucagon receptor agonism, the unique feature of retatrutide, increases resting energy expenditure and hepatic lipid oxidation. This is a fundamentally different lever than appetite suppression: it raises energy output instead of only lowering energy input.

That distinction matters in practice. Semaglutide is essentially an appetite and glycemic tool: it works by reducing energy intake, and its 94 percent sequence homology to native GLP-1, combined with a C18 fatty diacid chain, gives it a roughly seven-day half-life. Tirzepatide pairs GLP-1 with GIP via a C20 fatty diacid and reaches about five days of half-life, producing what Lilly describes as a synergistic incretin effect. Retatrutide attempts to recruit whole-body energy metabolism by adding balanced glucagon agonism, with a half-life of roughly six days.

In simple terms: semaglutide asks less of the metabolism, tirzepatide asks more of the incretin axis, and retatrutide tries to change the energy balance equation itself.

The trade-off is interpretive complexity. The more receptors a peptide engages, the harder it is to attribute a downstream effect to a single mechanism. Heart rate, gastrointestinal motility, liver enzymes and body composition can all shift, and separating the contribution of each receptor requires careful study design.

The reference numbers come from three different trial programs, and they are not directly comparable. Populations, titration schedules, baseline BMIs, durations and statistical estimands all differ between trials.

Semaglutide 2.4 mg delivered about 14.9 percent mean body weight loss at 68 weeks in STEP-1, the dataset behind the Wegovy approval, and the SELECT cardiovascular outcomes trial later demonstrated a roughly 20 percent relative reduction in major adverse cardiovascular events. Tirzepatide reached up to 20.9 percent mean weight loss at 72 weeks in SURMOUNT-1 at the 15 mg dose. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine, then showed tirzepatide produced 20.2 percent mean weight loss versus 13.7 percent for semaglutide within the same trial, same population, same protocol. At the responder level the gap widened: 31.6 percent of tirzepatide participants lost at least 25 percent of their body weight versus 16.1 percent on semaglutide.

Retatrutide sits at a different stage of maturity. Its phase 2 obesity trial, published in the New England Journal of Medicine in 2023, reported 24.2 percent mean weight loss at 48 weeks in the highest-dose cohort. In May 2026, Lilly announced topline results from the pivotal phase 3 TRIUMPH-1 trial: participants on 12 mg lost an average of 28.3 percent of body weight over 80 weeks from an average baseline BMI of about 40, with 45.3 percent achieving at least 30 percent loss and 65.3 percent dropping below a BMI of 30. In a blinded extension through 104 weeks, participants with a baseline BMI of at least 35 who continued on 12 mg reached an average of 30.3 percent weight loss. TRIUMPH-2, in people with type 2 diabetes, and TRIUMPH-3, in people with established cardiovascular disease, had not yet reported at the time of writing.

Bottom line: No randomized head-to-head of retatrutide versus tirzepatide had been published as of this writing. The directional pattern is nonetheless consistent: each additional receptor target in this family has been associated with a higher top-end weight reduction, and with a larger burden of gastrointestinal events that must be managed through slow titration.

Gastrointestinal effects dominate the adverse-event profile of all three compounds, and they cluster during dose escalation. In SURMOUNT-5, fewer participants discontinued tirzepatide for adverse events than semaglutide (6.1 percent versus 8.0 percent), and specifically for gastrointestinal events (2.7 percent versus 5.6 percent). Vomiting was less common on tirzepatide (15.0 percent versus 21.3 percent). The trade-off was injection-site reactions, which occurred in 8.6 percent of tirzepatide participants versus 0.3 percent on semaglutide. There were no treatment-attributed deaths in either arm.

TRIUMPH-1 illustrates the dose-response of tolerability clearly. At 4, 9 and 12 mg of retatrutide, nausea occurred in 28.6, 38.4 and 42.4 percent of participants respectively, versus 14.8 percent on placebo, with correspondingly higher rates of diarrhea, constipation and vomiting at the top dose. Two signals worth noting in research protocols were dysesthesia, reported by 12.5 percent of the 12 mg group versus 0.9 percent on placebo, and elevated urinary tract infection rates (8.4 percent versus 5.3 percent); both were mostly mild to moderate and resolved during treatment. Discontinuation due to adverse events at 12 mg reached 11.3 percent versus 4.9 percent on placebo.

What this means for a research protocol: slow, stepwise titration is not optional for any of these peptides, and body composition should be tracked rather than scale weight alone. Aggressive caloric deficit in the GLP-1 class can carry a meaningful lean-mass cost, which is one reason researchers pair these compounds with resistance-training or anabolic protocols only after careful design.

As lyophilized research peptides, all three are handled the same way: stored frozen, reconstituted with bacteriostatic water and used within the documented stability window. Practical reference points from the BiohackTested compound guides:

• Semaglutide is typically supplied as a 5 mg vial and reconstituted with 2.0 ml of BAC water for a 2.5 mg/ml solution; common research doses run 0.25 to 1.0 mg weekly on a titration protocol.
• Tirzepatide is typically supplied as a 15 mg vial; 2.0 ml of BAC water yields 7.5 mg/ml, and common research doses run 2.5 to 7.5 mg weekly.
• Retatrutide is typically supplied as a 10 mg vial and reconstituted with 2.0 ml of BAC water; research doses are commonly explored between 1.0 and 4.0 mg weekly, well below clinical trial doses.

Half-lives of five to seven days support once-weekly protocols in all three cases. Always confirm the net peptide weight via third-party HPLC before calculating doses, and use the reconstitution calculator to convert mg and BAC water volume into exact insulin syringe units.

Verification is where the comparison becomes a purchase decision. These are among the most counterfeited peptides on the research market because clinical demand is enormous. A vial labeled semaglutide may contain anything from a cheap GLP-1 analog to nothing at all. Every batch should carry an independent third-party HPLC purity certificate above 99 percent with mass spectrometry confirmation, a documented fill-weight audit, and an endotoxin test. Vendors that publish batch-linked COAs from Janoshik, MZ Biolabs or equivalent laboratories are the only ones worth comparing in the first place.

• Semaglutide: the benchmark with maximum evidence maturity and the cleanest single-receptor pharmacology. Choose it when the research question is specifically about GLP-1 receptor agonism.
• Tirzepatide: the strongest validated dual-agonist tool, with the largest obesity dataset and a head-to-head win over semaglutide. Choose it when the question is about dual incretin biology.
• Retatrutide: the frontier molecule for testing whether glucagon-mediated energy expenditure and hepatic effects add value beyond appetite suppression. Loud phase 2 and TRIUMPH-1 signals, but less independent reference data and no approved clinical status.

Bottom line: choose the compound that matches the research question, not the one with the biggest headline number. And verify every vial before it enters a protocol.